Tivic Health Systems Rebrands as Valion Bio, Pivoting to Late-Stage Biopharma with Government-Backed Asset
TIVC sits 83% above its 52-week low of $0.722.
Summary
Tivic Health Systems, Inc. is rebranding as Valion Bio, Inc. and changing its ticker to VBIO, reflecting a complete strategic pivot from consumer medical devices to a late-stage biopharmaceutical company focused on a government-priority asset.
Key Events · Corporate Governance and Compliance · TIVC
-
Corporate Name and Ticker Change
Effective April 28, 2026, the company will change its corporate name to Valion Bio, Inc. and its Nasdaq ticker symbol from 'TIVC' to 'VBIO'.
-
Strategic Business Transformation
The rebrand signifies a complete strategic pivot from a consumer medical device business to a focused late-stage biopharmaceutical platform.
-
Focus on Entolimod™ and Government Contracts
The company's lead drug candidate, Entolimod™, a TLR5 agonist for Acute Radiation Syndrome (ARS), is being advanced for potential inclusion in the U.S. Strategic National Stockpile, with engagement with BARDA and other government agencies for a potentially nine-figure non-dilutive revenue event.
-
Velocity Bioworks CDMO Subsidiary
The wholly-owned CDMO subsidiary, Velocity Bioworks, provides internal manufacturing capabilities for Entolimod and operates as a standalone CDMO, aiming to build a self-sustaining, cash flow-positive operation independent of drug development timelines.
Analysis · TIVC · Industrial Applications And Services
This filing announces a significant strategic transformation for Tivic Health Systems, Inc., rebranding as Valion Bio, Inc. and changing its ticker to VBIO. The company is shifting entirely from a consumer medical device business to a late-stage biopharmaceutical platform. This pivot is anchored by Entolimod™, a novel drug candidate for Acute Radiation Syndrome (ARS) with FDA Fast Track and Orphan Drug designations, actively engaged with government agencies for potential inclusion in the U.S. Strategic National Stockpile, which could represent a substantial non-dilutive revenue opportunity. The company also highlights its wholly-owned CDMO subsidiary, Velocity Bioworks, as a strategic asset for internal manufacturing and a potential source of independent, non-dilutive revenue. This rebrand, following recent filings for dilutive financing, signals a new strategic direction aimed at higher-value biopharmaceutical markets.
At the time of this filing, TIVC was trading at $1.32 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $0.72 to $7.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.